Related Experiment Video

Updated: Dec 11, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.7K

Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction

Prathap Kanagala1,2, Jayanth R Arnold1, Jamal N Khan1

  • 1Department of Cardiovascular Sciences and the National Institute for Health Research (NIHR) Leicester, Biomedical Research Centre, Leicester, UK.

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|August 18, 2020
PubMed

Insights

Plasma Tenascin-C is elevated in heart failure with preserved ejection fraction (HFpEF) patients compared to controls. Higher Tenascin-C levels predict adverse clinical outcomes in HFpEF.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Tenascin-C is a known marker of interstitial fibrosis.
  • Its role in heart failure with preserved ejection fraction (HFpEF) and its association with clinical outcomes require further investigation.

Purpose of the Study:

  • To compare plasma Tenascin-C levels between HFpEF patients and asymptomatic controls.
  • To determine if plasma Tenascin-C levels correlate with clinical severity and predict adverse outcomes in HFpEF.

Main Methods:

  • A prospective, observational study included 172 age- and sex-matched subjects (130 HFpEF, 42 controls).
  • Phenotyping involved 20 plasma biomarkers, echocardiography, cardiac MRI, and 6-minute walk testing.
  • The primary endpoint was a composite of all-cause death or HF hospitalization.

Main Results:

  • Plasma Tenascin-C was significantly higher in HFpEF patients (13.7 ng/ml) versus controls (11.1 ng/ml) (p < 0.0001).
  • Tenascin-C positively correlated with markers of clinical severity, interstitial fibrosis, cardiomyocyte stress, inflammation, and renal dysfunction (p < 0.05).
  • During a median follow-up of 1428 days, Tenascin-C independently predicted adverse outcomes (adjusted HR 1.755, p < 0.0001).

Conclusions:

  • Plasma Tenascin-C is elevated in HFpEF patients compared to controls.
  • Elevated Tenascin-C is a strong independent predictor of adverse clinical outcomes in HFpEF.
Abstract

Keywords:
Tenascin-Cbiomarkersheart failure with preserved ejection fractioninflammationinterstitial fibrosisprognosis

More Related Videos

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

904
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
407
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
653
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
549
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
242